Lercanidipine Medreg (Lercanidipine Hydrochloride)

Lercanidipine is indicated for the management of high blood pressure within the antihypertensive drug class.

• Hypertension: lowers elevated systolic and diastolic blood pressure to reduce cardiovascular risk.
• Essential hypertension: provides long‑lasting blood pressure control in primary hypertension.
• Isolated systolic hypertension: effectively reduces systolic pressure in elderly patients with isolated systolic elevation.

• Lercanidipine selectively blocks L‑type calcium channels on vascular smooth muscle, inhibiting calcium influx. This causes dose‑dependent relaxation of arterial smooth muscle, leading to vasodilation, reduced peripheral resistance, and a consequent decrease in systemic blood pressure without significant negative inotropic effects.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Headache: mild to moderate pressure sensation.
• Flushing: transient warmth and reddening of the skin.
• Peripheral edema: swelling of ankles or lower legs.
• Dizziness: sensation of light‑headedness, especially after standing.
• Tachycardia: mild increase in heart rate.
• Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure causing fainting.
• Angioedema: swelling of face, lips, tongue, or airway.
• Myocardial infarction: rare occurrence of heart attack.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Allergic reactions: rash, pruritus, or urticaria.
• Cardiac arrhythmias: irregular heart rhythms.

Before initiating therapy with Lercanidipine, consider the following safety measures.

• Blood pressure monitoring: regularly assess to avoid excessive hypotension.
• Hepatic impairment: use cautiously and adjust if liver function is compromised.
• Elderly patients: start at the lowest effective dose and monitor for dizziness.
• Concomitant antihypertensives: watch for additive blood‑pressure‑lowering effects.
• Hypersensitivity: discontinue if signs of allergic reaction appear.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, influencing its efficacy and safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels and risk of hypotension.
• Grapefruit juice: can markedly raise drug concentrations.
• Other potent vasodilators (e.g., nitroglycerin): may cause severe blood‑pressure drops.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness.

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive response.
• Diuretics and beta‑blockers: require careful titration to avoid excessive hypotension.